6-bromo-3-[3-(2-chloro-7-ethoxy-3-quinolinyl)acryloyl]-4-phenyl-2(1H)-quinolinone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-bromo-3-[3-(2-chloro-7-ethoxy-3-quinolinyl)acryloyl]-4-phenyl-2(1H)-quinolinone
• 英文别名: 6-bromo-3-[(E)-3-(2-chloro-7-ethoxyquinolin-3-yl)prop-2-enoyl]-4-phenyl-1H-quinolin-2-one
• 化学式: C₂₉H₂₀BrClN₂O₃
• 分子量: 559.8
• InChiKey: BUXUOSFXEORXCU-UKTHLTGXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  68.3
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：Cai Xiong Sui

  公开号：US20050165053A1

  公开（公告）日：2005-07-28

  The present invention is directed to substituted 4-Aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1H)-quinolinones and analogs thereof, represented by the general Formula I: wherein Ar 1 , Ar 2 , R 1 -R 6 and R 12 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. The compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及替代的4-芳基-3-(3-芳基-1-氧代-2-丙烯基)-2(1H)-喹啉酮及其类似物，由通式I所表示，其中Ar1，Ar2，R1-R6和R12在此被定义。本发明还涉及发现具有式I的化合物是caspase的激活剂和凋亡诱导剂。本发明的化合物可用于在许多临床情况下诱导细胞死亡，其中存在异常细胞的不受控制的生长和扩散。
• Compounds for the treatment of diseases
  申请人：Brown Daniel Alan

  公开号：US20050215542A1

  公开（公告）日：2005-09-29

  The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds of the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

  该发明涉及公式（1）的化合物，以及用于制备这些衍生物的中间体的制备过程，包含这些衍生物的组合物和使用这些衍生物的方法。本发明的化合物可用于众多疾病、疾病和状况，特别是炎症、过敏和呼吸道疾病、疾病和状况。
• Method for quantitatively determining specific groups constituting heparins or low molecular wieght heparins using HPLC
  申请人：Aventis Pharma S.A.

  公开号：EP1580197A1

  公开（公告）日：2005-09-28

  A method for analysing heparins or low-molecular-weight heparins, characterized in that the sample to be assayed is depolymerized by the action of heparinases and then, where appropriate, the depolymerizate obtained is reduced and then an analysis is carried out by high performance liquid chromatography.

  一种分析肝素或低分子量肝素的方法，其特征在于待测样品在肝素酶的作用下解聚，然后在适当的情况下还原解聚物，再用高效液相色谱法进行分析。
• Heteroaryl inhibitors of PAD4
  申请人：PADLOCK THERAPEUTICS, INC.

  公开号：US11026937B2

  公开（公告）日：2021-06-08

  The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

  本发明提供了可用作 PAD4 抑制剂的化合物、其组合物以及治疗 PAD4 相关疾病的方法。
• Method for quantitatively determining specific groups constituting heparins or low molecular weight heparins
  申请人：Aventis Pharma S.A.

  公开号：US20040265943A1

  公开（公告）日：2004-12-30

  A method for analysing heparins or low-molecular-weight heparins, characterized in that the sample to be assayed is depolymerized by the action of heparinases and then, where appropriate, the depolymerizate obtained is reduced and then an analysis is carried out by high performance liquid chromatography.

  一种分析肝素或低分子量肝素的方法，其特征在于待测样品在肝素酶的作用下解聚，然后在适当的情况下还原解聚物，再用高效液相色谱法进行分析。